135 related articles for article (PubMed ID: 38336503)
1. An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative Intent.
Rajagopal S; Yao X; Abadir W; Baetz TD; Easson AM; Knight G; McWhirter E; Nessim C; Rosen CF; Sun A; Wright FC; Petrella TM
Clin Oncol (R Coll Radiol); 2024 Apr; 36(4):243-253. PubMed ID: 38336503
[TBL] [Abstract][Full Text] [Related]
2. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
3. Single-agent interleukin-2 in the treatment of metastatic melanoma.
Petrella T; Quirt I; Verma S; Haynes AE; Charette M; Bak K;
Curr Oncol; 2007 Feb; 14(1):21-6. PubMed ID: 17576460
[TBL] [Abstract][Full Text] [Related]
4. An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Consolidation or Maintenance Systemic Therapy for Newly Diagnosed Stage II, III, or IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma.
Hirte H; Yao X; Ferguson SE; May T; Elit L
Curr Oncol; 2021 Mar; 28(2):1114-1124. PubMed ID: 33804587
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
Reece D; Imrie K; Stevens A; Smith CA;
Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. An evidence-based guideline on the application of molecular testing in the diagnosis, prediction of prognosis, and selection of therapy in non-GIST soft tissue sarcomas.
Yao X; Ghert M; Dickson BC; Popovic S; Purgina BM; Verma S; Werier J; Kandel RA
Cancer Treat Rev; 2020 Apr; 85():101987. PubMed ID: 32092619
[TBL] [Abstract][Full Text] [Related]
9. Biochemotherapy for the treatment of metastatic malignant melanoma: a clinical practice guideline.
Verma S; Petrella T; Hamm C; Bak K; Charette M;
Curr Oncol; 2008 Apr; 15(2):85-9. PubMed ID: 18454183
[TBL] [Abstract][Full Text] [Related]
10. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
Teede HJ; Misso ML; Costello MF; Dokras A; Laven J; Moran L; Piltonen T; Norman RJ;
Fertil Steril; 2018 Aug; 110(3):364-379. PubMed ID: 30033227
[TBL] [Abstract][Full Text] [Related]
11. Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.
Wright FC; Kellett S; Hong NJL; Sun AY; Hanna TP; Nessim C; Giacomantonio CA; Temple-Oberle CF; Song X; Petrella TM
Curr Oncol; 2020 Jun; 27(3):e318-e325. PubMed ID: 32669939
[TBL] [Abstract][Full Text] [Related]
12. Surveillance evaluations in patients with stage I, II, III, or resectable IV melanoma who were treated with curative intent: A systematic review.
Rajagopal S; Yao X; Abadir W; Baetz TD; Easson A; Knight G; McWhirter E; Nessim C; Rosen CF; Sun A; Wright FC; Petrella TM
Surg Oncol; 2024 Jun; 54():102077. PubMed ID: 38657486
[TBL] [Abstract][Full Text] [Related]
13. Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.
Petrella TM; Fletcher GG; Knight G; McWhirter E; Rajagopal S; Song X; Baetz TD
Curr Oncol; 2020 Feb; 27(1):e43-e52. PubMed ID: 32218667
[TBL] [Abstract][Full Text] [Related]
14. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
Teede HJ; Misso ML; Costello MF; Dokras A; Laven J; Moran L; Piltonen T; Norman RJ;
Hum Reprod; 2018 Sep; 33(9):1602-1618. PubMed ID: 30052961
[TBL] [Abstract][Full Text] [Related]
15. Management of single brain metastasis: a practice guideline.
Mintz A; Perry J; Spithoff K; Chambers A; Laperriere N
Curr Oncol; 2007 Aug; 14(4):131-43. PubMed ID: 17710205
[TBL] [Abstract][Full Text] [Related]
16. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.
Jonker D; Rumble RB; Maroun J;
Curr Oncol; 2006 Oct; 13(5):173-84. PubMed ID: 22792014
[TBL] [Abstract][Full Text] [Related]
17. Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer.
Rodrigues G; Yao X; Loblaw DA; Brundage M; Chin JL;
Can Urol Assoc J; 2013; 7(5-6):E411-6. PubMed ID: 23826053
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide for the treatment of metastatic melanoma.
Quirbt I; Verma S; Petrella T; Bak K; Charette M;
Curr Oncol; 2007 Feb; 14(1):27-33. PubMed ID: 17576461
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline.
Earle CC; Maroun J; Zuraw L;
Can J Surg; 2002 Dec; 45(6):438-46. PubMed ID: 12500920
[TBL] [Abstract][Full Text] [Related]
20. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome†.
Teede HJ; Tay CT; Laven J; Dokras A; Moran LJ; Piltonen TT; Costello MF; Boivin J; Redman LM; Boyle JA; Norman RJ; Mousa A; Joham AE;
Hum Reprod; 2023 Sep; 38(9):1655-1679. PubMed ID: 37580037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
